Opioid-induced constipation: challenges and therapeutic opportunities (Q37846099)

24 August 2017

1 reference

title

Opioid-induced constipation: challenges and therapeutic opportunities (English)

1 reference

24 August 2017

0 references

1 reference

1

Michael Camilleri

1 reference

24 August 2017

language of work or name

English

0 references

publication date

22 February 2011

1 reference

The American Journal of Gastroenterology

24 August 2017

published in

1 reference

24 August 2017

volume

106

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

835-42; quiz 843

1 reference

Prevalence of chronic benign pain disorder among adults: a review of the literature

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

A flood of opioids, a rising tide of deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Opioid prescriptions for chronic pain and overdose: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Opioids in chronic non-cancer pain: systematic review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Incidence, prevalence, and management of opioid bowel dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Opioid-induced bowel dysfunction: pathophysiology and potential new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Opioids and the gut: pharmacology and current clinical experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Function of opioids in the enteric nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Insights into opioid action in the intestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Mu-opioid and noradrenergic α(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Pharmacogenetics of low dose clonidine in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled pha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Oral naloxone reverses opioid-associated constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Long-Term Safety and Efficacy of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules, a Novel Formulation Containing Morphine and Sequestered Naltrexone, in Patients with Chronic, Moderate to Severe Pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

A review of the potential role of methylnaltrexone in opioid bowel dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Methylnaltrexone for opioid-induced constipation in advanced illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

The effects of methylnaltrexone alone and in combination with acutely administered codeine on gastrointestinal and colonic transit in health

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Alvimopan, a selective peripherally acting mu-opioid antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Validation of a Bowel Function Diary for Assessing Opioid-Induced Constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

Alvimopan∗∗Alvimopan is the official USAN name adopted as of press time. (ADL 8-2698) Is a Novel Peripheral Opioid Antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2011.30

21 January 2018

Identifiers

DOI

10.1038/AJG.2011.30

1 reference

24 August 2017

1 reference